Table 3.
Patient characteristics
| Study | Treatment | Age (years)* | Males (%) | CHADS2 score* | History of stroke/TIA (%) | History of hypertension (%) | Heart failure (%) | History of MI (%) | Diabetes (%) | TTR (%)* |
|---|---|---|---|---|---|---|---|---|---|---|
| ACTIVE-A18 | ASA + C | 70.9 | 58.6 | 2 | 13.2 | 85.3 | 32.9 | 13.9 | 19.5 | NA |
| ASA | 71.1 | 57.8 | 2 | 13 | 84.9 | 33.2 | 14.6 | 19.2 | ||
| ACTIVE-W6 | ASA + C | 70.2 | 67 | 2 | 15 | 83 | 30 | 17 | 21 | 63.8 |
| Warfarin | 70.2 | 66 | 2 | 15 | 82 | 31 | 18 | 21 | ||
| AFASAK19 | ASA | 75.1^ | 55 | NR | 5 | 33 | 54 | 7 | 8 | NA |
| Placebo | 74.6^ | 54 | NR | 6 | 31 | 51 | 8 | 10 | ||
| AFASAK 220,21 | ASA | 73.1 | 65 | NR | 8 | 43 | 70 | 7 | 10 | 73 |
| Warfarin | 73.2 | 57 | NR | 8 | 47 | 70 | 8 | 14 | ||
| ARISTOTLE22 | Apixaban | 70^ | 64.5 | 2.1 | 19.2‡ | 87.3 | 35.5§ | 14.5 | 25 | 62.2^ |
| Warfarin | 70^ | 65 | 2.1 | 19.7‡ | 87.6 | 35.4§ | 13.9 | 24.9 | ||
| AVERROES9 | Apixaban | 70 | 59 | 2 | 14 | 86 | 40 | NR | 19 | NA |
| ASA | 70 | 58 | 2.1 | 13 | 87 | 38 | NR | 20 | ||
| BAFTA23 | ASA | 81.5 | 54 | NR | 12 | 55 | 19 | 12 | 13 | 67 |
| Warfarin | 81.5 | 55 | NR | 13 | 53 | 20 | 10 | 14 | ||
| CAFA24 | Placebo | 67.4 | 73.3 | NR | 4.2 | 34 | 20.4 | 12 | 10 | 43.7^ |
| Warfarin | 68 | 75.9 | NR | 3.2 | 43.3 | 23.5 | 15 | 13.9 | ||
| EAFT25 | ASA | 73 | 59 | NR | 100 | 49 | 11 | 7 | 13 | NA |
| Placebo | 73 | 53 | NR | 100 | 47 | 12 | 9 | 13 | ||
| ENGAGE-AF26 | Edoxaban HD | 72^ | 62.1 | 2.8 | 28.1 | 93.7 | 58.2 | NR | 36.4 | 68.4^ |
| Edoxaban LD | 72^ | 61.2 | 2.8 | 28.5 | 93.5 | 56.6 | NR | 36.2 | ||
| Warfarin | 72^ | 62.5 | 2.8 | 28.3 | 93.6 | 57.5 | NR | 35.8 | ||
| JAST27 | ASA | 65.5 | 71.1 | NR | NR | 36.6 | 8.3 | NR | 12.7 | NA |
| Placebo | 64.8 | 69.7 | NR | NR | 40.4 | 10.1 | NR | 15.3 | ||
| LASAF33 | ASA | 66 | 55.5 | NR | NR | 53 | NR | NR | 5 | NA |
| Placebo | 67 | 49.5 | NR | NR | 49 | NR | NR | 9 | ||
| RE-LY7 | Dabigatran 110 | 71.4 | 64.3 | 2.1 | 19.9 | 78.8 | 32.2 | 16.8 | 23.4 | 64 |
| Dabigatran 150 | 71.5 | 63.2 | 2.2 | 20.3 | 78.9 | 31.8 | 16.9 | 23.1 | ||
| Warfarin | 71.6 | 63.3 | 2.1 | 19.8 | 78.9 | 31.9 | 16.1 | 23.4 | ||
| ROCKET-AF8 | Rivaroxaban | 73^ | 60.3 | 3.5 | 54.9 | 90.3 | 62.6 | 16.6 | 40.4 | 55^ |
| Warfarin | 73^ | 60.3 | 3.5 | 54.6 | 90.8 | 62.3 | 18 | 39.5 | ||
| SPAF I31 | ASA | 67 | 71 | NR | 6 | 53 | 20 | 7 | 16 | NA |
| Placebo | 67 | 70 | NR | 7 | 52 | 20 | 8 | 19 | ||
| WASPO32 | ASA | 82.6^ | 54 | NR | 0 | 46 | NR | NR | 5 | 69.2 |
| Warfarin | 83.5^ | 39 | NR | 0 | 49 | NR | NR | 3 |
Notes:
*
Data are mean values unless otherwise specified;
^
median values;
‡
includes history of systemic embolism;
§
includes history of reduced left ventricular function.
Abbreviations: ASA, acetylsalicylic acid (aspirin); C, clopidogrel; LD, low dose; HD, high dose; TIA, transient ischemic attack; MI, myocardial infarction; TTR, time in therapeutic range; NA, not applicable; NR, not reported.